Abstract:Ho Kyung Seo , Eui Hyun Jung , Geehyun Song Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea Comment on: Achard V, Fournier B, D'Haese D, et al . Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial. Eur Urol Oncol 2024;7:982-5. Keywords: Radiotherapy; bladder cancer; carcinoma in situ (CIS); radiosensitizer Submitted Sep 09, 2024. Accepted for publication Nov 05, 2024. Published online Nov 28, 2024. doi: 10.21037/tau-24-480 The treatment options for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) are evolving, with an increasing focus on bladder-sparing therapies (1,2). Radical cystectomy, although considered the standard of care, is often declined by patients or is not feasible because of its significant impact on quality of life and high surgical risks (3). Achard et al. proposed a novel combination of moderate hypofractionated radiotherapy with a radiosensitizer as a viable alternative for patients with BCG-unresponsive NMIBC with carcinomain situ(CIS) who are either ineligible for or decline radical cystectomy (4). The European Organisation for Research and Treatment of Cancer (EORTC) conducted a phase 2 trial (EORTC 2235) to investigate the efficacy of combining moderate hypofractionated radiotherapy with a radiosensitizer (4). This open-label, single-arm, multicenter study enrolled patients with histologically confirmed BCG-unresponsive CIS of the bladder, with or without high-grade Ta or T1 papillary masses. The treatment involved the administration of external beam radiotherapy (EBRT) in 20 fractions over 4 weeks, combined with 1 of 4 radiosensitizers: carbogen and nicotinamide, 5-fluorouracil and mitomycin C, cisplatin, or gemcitabine (4). The primary endpoint was the complete response (CR) rate (CRR) at 6 months. Secondary endpoints included durability or CR, progression-free survival, radical cystectomy free survival, overall survival, safety, and quality-of-life metrics (4). Recent systematic reviews and studies have demonstrated varying degrees of success with bladder-sparing therapies for BCG-unresponsive NMIBC. For instance, Li et al. [2020] reported median CRRs of 26% at 6 months and 17% at 12 months for CIS (5). Shah et al. [2020] emphasized the variability in trial outcomes due to differences in patient populations and definitions of BCG failure, underlining the importance of robust evaluation of new therapeutic candidates (6). The combination of EBRT and radiosensitizers is promising. James et al. [2012] found that synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer compared to that with radiotherapy alone, without a significant increase in adverse events (7). The study by Achard et al. adds to this body of evidence, suggesting that combining radiotherapy with a radiosensitizer can be a viable alternative to radical cystectomy for patients with BCG-unresponsive NMIBC (4). When compared to existing treatments, such as intravesical instillation of newer agents like pembrolizumab, nadofaragene firadenovec, IL-15 superagonists, or TAR 200 or systemic therapy with pembrolizumab, combined radiotherapy with a radiosensitizer was shown to be equally efficacious (8-11) ( Table 1 ). The nadofaragene firadenovec study had the largest sample size, with 157 patients enrolled (9). The radiotherapy study had the smallest planned sample size of 50 patients, which reflects its exploratory phase 2 design. The EORTC 2235 trial used a Simon's two-stage design to determine the number of patients (4). The null hypothesis assumed a 30% CRR, with an alternative hypothesis of 50% CR (4). This two-stage design allows for early termination if the treatment is not effective, thereby minimizing the exposure of patients to potentially ineffective treatments (4). However, it carries inherent risks of early termination, which might preclude the identification of beneficial therapies (4). Other studies, such as the QUILT-3.032 study, opt for larger sample sizes to ensure a more comprehensive evaluation, though at a higher cost and greater patient burden (10). Dahl et al. reported on a phase 2 trial of trimodality therapy (TMT) for BCG-unresponsive high-grade T1 bladder cancer, with a 3-year freedom from cystectomy rate of 88%, underscoring the potential of TMT as a viable bladder-preserving alternative (12). Additionally, Hahn et al. investigated durvalumab combined with BCG or radiotherapy in BCG-unresponsive NMIBC -Abstract Truncated-

Einsatz von TAR-200 und Cetrelimab bei Patienten mit NMIBC nach BCG-Therapie, die keine Zystektomie erhalten

Blasenerhalt bei erwachsenen Patienten mit muskel-invasivem Blasenkarzinom (MIBC), die für eine radikale Zystektomie nicht infrage kommen oder diese ablehnen

Kombinationstherapie beim Hochrisiko- nicht-muskelinvasiven Blasenkarzinom (HR-NMIBC) mit und ohne BCG-Vorbehandlung

Kohortenstudie beim metastasierten und nicht resezierbaren, lokal fortgeschrittenen Urothelkarzinom

A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin (BCG) for patients with BCG-exposed, high-grade, non-muscle–invasive bladder cancer.

Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).

Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.

First-Line-Therapie beim unbehandelten lokal fortgeschrittenen, inoperablen oder metastasierten Nierenzellkarzinom

Abstract PR005: Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer

Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.

Exploring radiotherapy combined with a radiosensitizer for Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ

Abstract B007: Urinary cytokine profiles reflect rationale for treatment with gemcitabine and Bacillus Calmette-Guérin (BCG) in BCG-exposed high-risk non-muscle invasive bladder cancer (NMIBC)

Perioperative Studie beim muskelinvasiven Blasenkarzinom (MIBC) mit Indikation zur radikalen Zystektomie

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

[Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer]

Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center

SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.

[New therapeutic approaches for non-muscle invasive bladder cancer-is organ preservation also possible after BCG (Bacillus Calmette Guérin)?]

Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Observation after Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gallbladder Carcinoma (ACTICCA-1): A Randomized, Multidisciplinary, Multinational Phase III Trial.

P1310 : Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Observation after Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gallbladder Carcinoma (ACTICCA-1) – a Randomized, Multidisciplinary, Multinational Phase III Trial

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.